 | • レポートコード：B-MOR-08354 • 出版社/出版日：Mordor Intelligence / 2018年5月28日 • レポート形態：英文、PDF、108ページ • 納品方法：Eメール（受注後2営業日） • 産業分類：Healthcare |
| Single User（1名様用） | ￥629,000 (USD4,250) | ▷ お問い合わせ |
| Team User（7名様用） | ￥666,000 (USD4,500) | ▷ お問い合わせ |
| Corporate User | ￥1,295,000 (USD8,750) | ▷ お問い合わせ |
• お支払方法：銀行振込（納品後、ご請求書送付）
レポート概要
| 本資料は、片頭痛治療の世界市場について調べ、片頭痛治療の世界規模、市場動向、市場環境、治療別（予防、根治）分析、治療薬別（トリプタン、麦角アルカロイド、その他）分析、アメリカ市場規模、ヨーロッパ市場規模、アジア市場規模、企業の競争環境、関連企業情報などをまとめた調査レポートです。 ・イントロダクション ・エグゼクティブサマリー ・片頭痛治療の世界市場インサイト ・片頭痛治療の世界市場環境 ・片頭痛治療の世界市場動向 ・片頭痛治療の世界市場規模 ・片頭痛治療の世界市場規模：治療別（予防、根治） ・片頭痛治療の世界市場規模：治療薬別（トリプタン、麦角アルカロイド、その他） ・片頭痛治療の世界市場：地域別市場規模・分析 ・片頭痛治療の北米市場規模・予測 ・片頭痛治療のアメリカ市場規模・予測 ・片頭痛治療のヨーロッパ市場規模・予測 ・片頭痛治療のアジア市場規模・予測 ・片頭痛治療のインド市場規模・予測 ・片頭痛治療の韓国市場規模・予測 ・関連企業情報・競争状況 |
The global migraine therapeutics market is expected to grow, at a CAGR of 8.4% over the forecast period, 2018-2023. Migraine is a complex neurological condition, characterized by frequent headaches that can last between four and 72 hours. The pain is often unilateral and pulsating in nature, which can often be worsened by physical activity. In most cases, migraine is associated with symptoms such as photophobia, phonophobia, osmophobia, nausea, vomiting, loss of appetite, and sometimes sensory disturbances.
Increasing prevalence of migraines
Migraine is a neurological disorder which can show incapacitating neurological symptoms. Migraine has been considered as the 3rd most prevalent disorder and 6th most disabling illness worldwide (according to the migraine trust). Migraine affects 18% of women and 6% of men in US. Migraine is mostly common in ages of 25 to 55. More than 4 million adults experience chronic daily migraine and it is estimated that approximately 1 out of 4 U.S. households has at least 1 person with migraine.
Due to the high unmet needs the major pharmaceutical companies have initiated several R&D programs to launch new molecules and are trying to increase the market access of the generic formulations across the globe. Moreover, the growing awareness of migraine therapeutics and improvement in accurate diagnosis of the condition are expected to favor the market expansion over the next few years.
Lack of Proper Diagnosis and Undiagnosed Cases
About 37 million people in US suffer from migraine, however, the numbers can be much higher owing to the number of undiagnosed silent migraines. A silent migraine is a type of migraine that does not have headache as one of its characteristic symptoms. Symptoms for a silent migraine revolve around the type of a migraine that it is, as in case of vestibular migraine particularly affects the vestibular system which controls balance. Which results in the primary symptoms to be may be dizziness, vertigo, nausea, and vomiting. In this case there is a lack of a headache. These patients who bypass proper diagnosis would otherwise have been potential users of migraine therapeutics. This will lead to the slowdown of the growth of this market along with other factors such as adverse effects of drugs, increased preference for alternative therapies and generic penetration.
Asia-Pacific to Emerge as the Fastest Growing Region
APAC is quickly emerging as the fastest-growing region in the migraine drugs market and is expected to grow at approximately a CAGR of about 6% during the forecast period. The primary reason for this region’s growth is the increasing the number of migraine cases and growing public awareness about the disease. India and China are the major markets in this region as the prevalence of migraine is high in these countries. The growing focus on new product launches and the high penetration of drug manufacturers will aid in the growth of the market in APAC during the forecast period.
Key Developments in the Market:
• March 2018 – A new type of medication for migraine headaches is currently being reviewed by the FDA, and if approved may provide safe, long-lasting relief for many by blocking the activation of a molecule involved in the pain process.
Major Players: ALLERGAN, AMIRALL, ASTRAZENECA, COLUCID PHARMACEUTICALS, GLAXOSMITHKLINE, MERCK, NEURAXON, NUPATHE, OPTINOSE, PFIZER, REDHILL BIOPHARMA, REVANCE THERAPEUTICS, SUDA, TEVA, VERNALIS AND ZOGENIX, amongst others.
Reasons to Purchase the Report
• Current and future migraine therapeutics market outlook in the developed and emerging markets
• Analysis of various perspectives of the market with the help of Porter’s five forces analysis
• The segment that is expected to dominate the market
• Regions that are expected to witness the fastest growth during the forecast period
• Identify the latest developments, market shares, and strategies employed by the major market players
• 3 months analyst support, along with the Market Estimate sheet (in Excel)
Customization of the Report
• This report can be customized to meet your requirements. Please connect with our representative, who will ensure you to get a report that suits your needs.
レポート目次1. Introduction
1.1 Market Definition
2. Research Methodology
3. Executive Summary
4. Key Inferences
5. Market Overview
5.1 Current Market Scenario
5.2 Porter’s Five Forces Analysis
5.2.1 Bargaining Power of Suppliers
5.2.2 Bargaining Power of Consumers
5.2.3 Threat of New Entrants
5.2.4 Threat of Substitute Product and Services
5.2.5 Competitive Rivalry Within the Industry
6. Drivers, Restraints, Opportunities, and Challenges Analysis (DROC)
6.1 Market Drivers
6.1.1 Growing Awareness about Migraine and its Treatment Options
6.1.2 Tentative Approval of Pipeline Candidates
6.1.3 High Unmet Needs
6.1.4 Increasing Prevalence of Migraines
6.2 Market Restraints
6.2.1 Lack of Proper Diagnosis and Undiagnosed Cases
6.2.2 Adverse Effects of Drugs
6.2.3 Increasing Preference for Alternative Therapies
6.3 Opportunities
6.4 Key Challenges
7. Market Segmentation
7.1 By Treatment
7.1.1 Preventative
7.1.2 Abortive
7.2 By Therapeutics
7.2.1 Triptans
7.2.2 Ergot alkaloids
7.2.3 Other
7.3 By Geography
7.3.1 North America
7.3.1.1 United States
7.3.1.2 Canada
7.3.1.3 Mexico
7.3.2 Europe
7.3.2.1 France
7.3.2.2 Germany
7.3.2.3 United kingdom
7.3.2.4 Italy
7.3.2.5 Spain
7.3.2.6 Rest of Europe
7.3.3 Asia-Pacific
7.3.3.1 India
7.3.3.2 Australia & New Zealand
7.3.3.3 South Korea
7.3.3.4 Others
7.3.4 Rest of the World
7.3.4.1 Saudi Arabia
7.3.4.2 Brazil
7.3.4.3 Others
8. Competitive Landscape
8.1 Mergers & Acquisition Analysis
8.2 Agreements, Collaborations, and Partnerships
8.3 New Products Launches
9. Key Players
9.1 Allergan
9.2 Amirall
9.3 AstraZeneca
9.4 CoLucid Pharmaceuticals
9.5 GlaxoSmithKline
9.6 Merck
9.7 NeurAxon
9.8 NuPathe
9.9 OptiNose
9.10 Pfizer
9.11 RedHill Biopharma
9.12 Revance Therapeutics
9.13 SUDA
9.14 Teva
9.15 Vernalis
9.16 Zogenix
*List not Exhaustive
10. Future of the Market